Cargando…

Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus

Lower extremity arterial disease (LEAD) is a major vascular complication of diabetes. Vascular endothelial cells dysfunction can exacerbate local ischemia, leading to a significant increase in amputation, disability, and even mortality in patients with diabetes combined with LEAD. Therefore, it is o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yang, Luo, Yuting, Hong, Jing, He, Huacheng, Dai, Lu, Zhu, Hong, Wu, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429832/
https://www.ncbi.nlm.nih.gov/pubmed/36060247
http://dx.doi.org/10.3389/fmolb.2022.929718
_version_ 1784779576480628736
author Pan, Yang
Luo, Yuting
Hong, Jing
He, Huacheng
Dai, Lu
Zhu, Hong
Wu, Jiang
author_facet Pan, Yang
Luo, Yuting
Hong, Jing
He, Huacheng
Dai, Lu
Zhu, Hong
Wu, Jiang
author_sort Pan, Yang
collection PubMed
description Lower extremity arterial disease (LEAD) is a major vascular complication of diabetes. Vascular endothelial cells dysfunction can exacerbate local ischemia, leading to a significant increase in amputation, disability, and even mortality in patients with diabetes combined with LEAD. Therefore, it is of great clinical importance to explore proper and effective treatments. Conventional treatments of diabetic LEAD include lifestyle management, medication, open surgery, endovascular treatment, and amputation. As interdisciplinary research emerges, regenerative medicine strategies have provided new insights to treat chronic limb threatening ischemia (CLTI). Therapeutic angiogenesis strategies, such as delivering growth factors, stem cells, drugs to ischemic tissues, have also been proposed to treat LEAD by fundamentally stimulating multidimensional vascular regeneration. Recent years have seen the rapid growth of tissue engineering technology; tissue-engineered biomaterials have been used to study the treatment of LEAD, such as encapsulation of growth factors and drugs in hydrogel to facilitate the restoration of blood perfusion in ischemic tissues of animals. The primary purpose of this review is to introduce treatments and novel biomaterials development in LEAD. Firstly, the pathogenesis of LEAD is briefly described. Secondly, conventional therapies and therapeutic angiogenesis strategies of LEAD are discussed. Finally, recent research advances and future perspectives on biomaterials in LEAD are proposed.
format Online
Article
Text
id pubmed-9429832
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94298322022-09-01 Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus Pan, Yang Luo, Yuting Hong, Jing He, Huacheng Dai, Lu Zhu, Hong Wu, Jiang Front Mol Biosci Molecular Biosciences Lower extremity arterial disease (LEAD) is a major vascular complication of diabetes. Vascular endothelial cells dysfunction can exacerbate local ischemia, leading to a significant increase in amputation, disability, and even mortality in patients with diabetes combined with LEAD. Therefore, it is of great clinical importance to explore proper and effective treatments. Conventional treatments of diabetic LEAD include lifestyle management, medication, open surgery, endovascular treatment, and amputation. As interdisciplinary research emerges, regenerative medicine strategies have provided new insights to treat chronic limb threatening ischemia (CLTI). Therapeutic angiogenesis strategies, such as delivering growth factors, stem cells, drugs to ischemic tissues, have also been proposed to treat LEAD by fundamentally stimulating multidimensional vascular regeneration. Recent years have seen the rapid growth of tissue engineering technology; tissue-engineered biomaterials have been used to study the treatment of LEAD, such as encapsulation of growth factors and drugs in hydrogel to facilitate the restoration of blood perfusion in ischemic tissues of animals. The primary purpose of this review is to introduce treatments and novel biomaterials development in LEAD. Firstly, the pathogenesis of LEAD is briefly described. Secondly, conventional therapies and therapeutic angiogenesis strategies of LEAD are discussed. Finally, recent research advances and future perspectives on biomaterials in LEAD are proposed. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9429832/ /pubmed/36060247 http://dx.doi.org/10.3389/fmolb.2022.929718 Text en Copyright © 2022 Pan, Luo, Hong, He, Dai, Zhu and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Pan, Yang
Luo, Yuting
Hong, Jing
He, Huacheng
Dai, Lu
Zhu, Hong
Wu, Jiang
Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
title Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
title_full Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
title_fullStr Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
title_full_unstemmed Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
title_short Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
title_sort advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429832/
https://www.ncbi.nlm.nih.gov/pubmed/36060247
http://dx.doi.org/10.3389/fmolb.2022.929718
work_keys_str_mv AT panyang advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus
AT luoyuting advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus
AT hongjing advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus
AT hehuacheng advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus
AT dailu advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus
AT zhuhong advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus
AT wujiang advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus